Claudins and hepatocellular carcinoma - 04/02/24

Doi : 10.1016/j.biopha.2023.116109

Wentao Wang ^a,^b,^{^{1
Wentao Wang and Yi Zhou contributed equally to this manuscript}}, Yi Zhou ^a,^c,^{^{1
Wentao Wang and Yi Zhou contributed equally to this manuscript}}, Wei Li ^a, Chengshi Quan ^a, Yanru Li ^a,^⁎
^a The Key Laboratory of Pathobiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, 126 Xinmin Avenue, Changchun, Jilin 130021, China
^b The Second Norman Bethune College of Clinical Medicine, Jilin University, Changchun 130021, China
^c The First Norman Bethune College of Clinical Medicine, Jilin University, Changchun 130021, China

^⁎Corresponding author.

Abstract

Hepatocellular carcinoma (HCC) has a high incidence and dismal prognosis, making it a significant global health burden. To change this, the development of new therapeutic strategies is imminent. The claudin (CLDN) family, as key components of tight junctions (TJs), plays an important role in the initiation and development of cancer. Dysregulated expression of CLDNs leads to loss of intercellular adhesion and aberrant cell signaling, which are closely related to cancer cell invasion, migration, and epithelial–mesenchymal transition (EMT). CLDN1, CLDN3, CLDN4, CLDN5, CLDN6, CLDN7, CLDN9, CLDN10, CLDN11, CLDN14, and CLDN17 are aberrantly expressed in HCC, which drives the progression of the disease. Consequently, they have tremendous potential as prognostic indicators and therapeutic targets. This article summarizes the aberrant expression, molecular mechanisms, and clinical application studies of different subtypes of CLDNs in HCC, with a particular emphasis on CLDN1.

Le texte complet de cet article est disponible en PDF.

Graphical Abstract

ga1

Le texte complet de cet article est disponible en PDF.

Highlights

●	The claudin family plays a vital role in the pathogenesis and progression of HCC.
●	Comprehensive analysis of different subtypes of claudins in HCC.
●	Most claudin subtypes are aberrantly expressed in HCC.
●	Claudin1 contributes to HCC’s malignant biological behavior in multiple ways.

Le texte complet de cet article est disponible en PDF.

Keywords : Claudins, Hepatocellular Carcinoma, CLDN1

Plan

Introduction

Background information on CLDNs

CLDNs’ expression in HCC

CRediT authorship contribution statement

Export

Vol 171

Article 116109- février 2024 Retour au numéro

Article précédent

The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers
Sarra Mestiri, Dina Moustafa Abo El-Ella, Queenie Fernandes, Takwa Bedhiafi, Salam Almoghrabi, Shayista Akbar, Varghese Inchakalody, Laila Assami, Shaheena Anwar, Shahab Uddin, Abdul Rehman Zar Gul, Mariam Al-Muftah, Maysaloun Merhi, Afsheen Raza, Said Dermime

| Article suivant

The relationship between Listeria infections and host immune responses: Listeriolysin O as a potential target
Zixuan Cong, Yan Xiong, Lyu Lyu, Beibei Fu, Dong Guo, Zhou Sha, Bo Yang, Haibo Wu

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Claudins and hepatocellular carcinoma - 04/02/24

Abstract

Graphical Abstract

Highlights

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL